// App-Quantinova.ai

3012 : Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.

Researchers

Presenter

  • Omid Hamid

Principal Investigators

  • Todd Michael Bauer

  • Alexander I. Spira

  • David C. Smith

  • Anthony J. Olszanski

  • Ahmad A. Tarhini

  • Primo Lara

  • Thomas Gajewski

  • Jeffrey S. Wasser

  • Sandip P. Patel

  • Virginia F. Borges

  • Ani Sarkis Balmanoukian

  • Emmett V. Schmidt

  • Yufan Zhao

  • Mark M. Jones

  • Tara C. Gangadhar

Medical Centers

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Virginia Cancer Specialists Research Institute, Fairfax, VA

  • University of Michigan, Ann Arbor, MI

  • Fox Chase Cancer Center, Philadelphia, PA

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

  • University of California, Davis School of Medicine, Sacramento, CA

  • The University of Chicago Medical Center, Chicago, IL

  • University of Connecticut Health Center, Farmington, CT

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • University of Colorado Cancer Center, Aurora, CO

  • Merck & Co., Inc., Kenilworth, NJ

  • Incyte Corporation, Wilmington, DE

  • Abramson Cancer Center, Philadelphia, PA

Locations

  • United States

Companies

  • Merck & Co., Inc.

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

  • epacadostat

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02178722

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved